Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092781
An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 129
- Registration Number
- NCT00092729
Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 576
- Registration Number
- NCT00092573
An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 831
- Registration Number
- NCT00092885
An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 30
- Registration Number
- NCT00092898
Sitosterolemia Extension Study (0653-004)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00092820
Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4086
- Registration Number
- NCT00092742
An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1873
- Registration Number
- NCT00092677
A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1398
- Registration Number
- NCT00092651
Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)
Phase 3
Terminated
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 49
- Registration Number
- NCT00092833
© Copyright 2024. All Rights Reserved by MedPath